Phylogica defies IPO blues

By Renate Krelle
Wednesday, 30 March, 2005

Perth-based functional proteomics company Phylogica (ASX: PYC) has defied recent biotech trends, with shares in the company opening today 37 per cent above their issue price of $0.20. At time of writing shares had slipped slightly and were trading at $0.25.

Major investors in the $5 million float included listed investment group Biotech Capital (ASX:BTC) and the Australian Heritage Group. Azure Capital managed the IPO, which was not underwritten.

Phylogica has used its technology to develop large libraries of naturally occurring protein fragments, which it will screen to identify drug candidates.

Related News

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...

Towards safer epilepsy treatment for pregnant women

New research conducted in organoids is expected to provide pregnant women with epilepsy safer...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd